Dupilumab in pregnancy: no major safety signals found
NCT ID NCT04173442
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study looked at whether the drug dupilumab, used for eczema or asthma, is safe during pregnancy. Researchers compared 581 pregnant women who took dupilumab with those who did not. They tracked birth defects, miscarriages, and infant health up to one year old to see if the drug caused any harm.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ASTHMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Regeneron Research Site
La Jolla, California, 92093-0934, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can tracking severe asthma over time unlock better treatments?
- Can pressurized breathing boost mucus clearance in lung disease?
- Can a simple breathing test unlock the secrets of chronic cough?
- Can a Breath-Activated inhaler match the standard for asthma control?
- Can a School-Home program tame childhood asthma?
- Could everyday supplements shield your lungs?